title: [Diagnosis and treatment for recurrent hepatocellular carcinoma].
abstract: In order to investigate the mechanism of recurrence of hepatocellular carcinoma (HCC), 322 patients with HCCs (size: < or = 3 cm) treated by percutaneous ethanol injection (PEI), transcatheter arterial embolization (TAE) or radiation therapy were evaluated. Cumulative recurrent rates of new lesions after the initial therapy were 25% (1-year), 57% (2-year) and 71% (3-year). In 116 patients whose tumors were multiple at the time of initial therapy, the recurrent rates were higher compared with 206 patients with a single tumor. In 228 of all patients, new lesions were observed in the noncancerous liver after initial therapy. We observed a single new lesion in 67% of the 134 patients, whose HCC was single at the time of initial therapy. In the remaining 33% of these patients, multiple new lesions were observed. As for the recurrence site, we found new lesions at a different segment of the liver from the initial HCC in 52% of these 134 patients. In the patients with multiple recurrent HCCs, the survival rates were lower in comparison with the patients whose recurrent HCC was single. In the patients whose new lesions were found within 1 year after the initial therapy, the survival rates were also lower compared with the patients whose new lesions were not detected during 1 year. In conclusion, the mechanism of multicentric occurrence may be closely correlated with the intrahepatic recurrence of HCC in consideration of the high incidence of recurrent rates of HCCs and their recurrent pattern.
authors.affiliation: First Dept. of Medicine, Chiba University, School of Medicine.
authors.forename: M
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: M
authors.initials: M
authors.lastname: Ebara
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
authors.forename: N
authors.initials: N
authors.lastname: Sugiura
authors.forename: H
authors.initials: H
authors.lastname: Saisho
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D004621:Embolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000431:Ethanol